Forward thinking to
reverse cell ageing

After graduating from the University of Warwick with a BSc (Hons) in Biochemistry, Helen spent 4 years working as a Research Assistant for Prof Sir Peter Ratcliffe at the Wellcome Trust Centre for Human Genetics, University of Oxford, whose research focussed on understanding the mechanisms by which cells sense and signal hypoxia. Prior to SENISCA, Helen spent 8 years working in the laboratory of Prof Rick Titball at the University of Exeter investigating the molecular biology of bacterial pathogens of humans and animals, with a strong emphasis on research leading to vaccines against infectious diseases. At SENISCA, Helen is part of the wet-lab R&D team tasked with validating our novel senotherapeutics in several different model systems.

Ling obtained her MSc degree in Biochemistry and PhD at the University of Bristol with Dr Sebastian Oltean, where she developed a specific interest in the modulation of alternative splicing regulators during EMT in cancer progression. Whilst finishing her PhD, Ling became increasingly interested in the detection of EGFR mutations in the plasma and urine of NSCLC patients, and as a result, continued working as a postdoctoral research associate with Dr Sebastian Oltean at the University of Exeter. At SENISCA, Ling is part of the wet-lab R&D team tasked with validating our novel senotherapeutics in several different model systems.

After completing her Biological Sciences BSc at the University of the West of England, Jemma went on to gain a PhD in Neuro-oncology from the University of Plymouth, where she performed global proteomic and phosphoproteomic analyses of the most common primary intracranial tumour, meningioma. As a postdoctoral researcher, Jemma has detailed the transcriptome-proteome landscape of meningioma to identify promising transcripts/proteins for the targeted treatment of meningioma and validated these candidates experimentally. At SENISCA, Jemma is part of the wet-lab R&D team tasked with validating our novel senotherapeutics in several different model systems.

Pouria started his career as a vet, initially in clinical practice and later as a chief technician in veterinary and medical diagnostic laboratories. He then completed a MSc in medical microbiology followed by a PhD in molecular biology at the University of Bradford where he investigated the role of a virus-encoded microRNA in modulation of host immune response. After his PhD, Pouria joined the laboratory of Prof. Noel Morgan and Sarah Richardson at the University of Exeter to study the complex interplay between enterovirus infection and host genetic and immunological factors in the pathogenesis of autoimmune type 1 diabetes. At SENISCA, Pouria is part of the wet-lab R&D team tasked with validating our novel serotherapeutic in several different model systems.

In 2015 Samantha graduated with a BSc (Hons) in Biomedical Science, and obtained her PhD in dental research in 2020 from the University of Plymouth. Samantha’s PhD spanned the fields of cell biology, microbiology, immunology, and tissue engineering, whereby she developed and characterised immunocompetent tissue-engineered models of the oral mucosa, to study host-response to oral pathogens. Before joining SENISCA, Samantha worked with team RNA at the University of Exeter developing an animal-free organotypic retinal model for the study of diabetic complications. At SENISCA, Samantha is part of the wet-lab R&D team tasked with validating our novel senotherapeutics in several different model systems.

Monica graduated from the University of Ghana with a BSc in Agricultural Engineering before moving to the UK to work as a Laboratory Assistant at the University of Exeter plant pathology and microbiology laboratories. Monica also worked in a synthetic biology laboratory as a research technician in Prof. John Love’s group for three years. She is nearing completion of her PhD, which investigates the use of alternative splicing as a therapeutic and diagnostic tool in diabetic nephropathy using small molecules. At SENISCA, Monica is a member of a wet-lab R&D team tasked with validating our novel senotherapeutics in several different model systems.

Darshan obtained his degree in Biological Sciences from the University of Leicester before completing a MSc in Drug Discovery and Pharmaceutical Science from the University of Nottingham. Darshan conducted a Genome-Wide Association study at the University of Leicester, focusing on identifying a link between 10q11 genes and coronary artery disease. During his masters, his research focussed on investigating the impact of the gut-microbiome-brain axis in cognitive function and learning, using Drosophila Melanogaster as a model.

After completing her BSc with a double major in biological sciences and molecular biology at Murdoch University, Western Australia, Jessica continued to gain a PhD in the Molecular Therapy laboratory at the Centre for Molecular Medicine and Innovative Therapeutics; where she specialised in antisense oligonucleotide-mediated alternative splicing strategies. At SENISCA, Jessica undertakes antisense oligonucleotide design and optimisation research.

Jodie graduated from Loughborough University with an MChem in Medicinal and Pharmaceutical Chemistry. Her masters project focused on optimising a new spectrometry technique to analyse the chemical composition of cells aiding in monitoring of cell growth. In 2022, Jodie joined the University of Exeter as a Graduate Research Assistant investigating a new therapeutic approach for diabetic kidney disease. At the end of her 12-month post, she will be joining Senisca as a PhD student focussing on neurodegenerative disease research.

At SENISCA Hubert's role involves the analysis of large biological datasets generated through sequencing projects to discover transcriptomic differences between senescent and non-senescent cells. Hubert obtained a PhD in Biochemistry and Molecular Biology from the University of Bordeaux and a MsC in Bioinformatics from Cranfield University. Hubert has worked for the Genetics department of the University of Cambridge, the European Bioinformatics Institute as well as Pfizer.